American Journal of Alzheimer's Disease and Other Dementias®

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Register here to gain access to SAGE's 500+ Journals Online

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brangman, S. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brangman, S. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
American Journal of Alzheimer's Disease and Other Dementias®, Vol. 18, No. 2, 79-84 (2003)
DOI: 10.1177/153331750301800204

Long-term cholinesterase inhibitor therapy for Alzheimer's disease: Implications for long-term care

Sharon A. Brangman, MD, FACP, AGSF

ADAC of Central New York, SUNY Upstate Medical University, Syracuse, New York.

As the population ages and Alzheimer's disease (AD) becomes more prevalent, nursing facilities will be faced with managing more AD patients than in previous decades. Managing this population will pose a significant challenge for the resources of long-term care facilities. In short-and long-term studies, cholinesterase (ChE) inhibitor treatment has been shown to benefit the symptoms of mild to moderate AD. Donepezil trials have extended this finding to patients with moderate to severe AD as well as the more severe symptoms of AD patients residing in nursing home settings. Results from long-term ChE inhibitor trials and the benefits that may be gained by treating AD patients residing in nursing facilities are presented.

Key Words: Alzheimer's disease • dementia • cholinesterase inhibitors • donepezil


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J Aging HealthHome page
L. L. Jervis and S. M. Manson
Cognitive Impairment, Psychiatric Disorders, and Problematic Behaviors in a Tribal Nursing Home
J Aging Health, April 1, 2007; 19(2): 260 - 274.
[Abstract] [PDF]

Home page
 AM J ALZHEIMERS DIS OTHER DEMENHome page
C. F. Lippa
An Individualized Approach to Treatment for Alzheimer's Disease, Pick's Disease, and Other Dementias.
American Journal of Alzheimer's Disease and Other Dementias, October 1, 2006; 21(5): 354 - 359.
[Abstract] [PDF]